Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Open-label, Randomized Study of the Safety and Preliminary Efficacy of Triple or Quadruple Combination DAAs With Ultra-short Duration Therapy in Subjects With HCV Genotype 1b Infection (YANGTZE Study)

Trial Profile

A Phase 2a, Open-label, Randomized Study of the Safety and Preliminary Efficacy of Triple or Quadruple Combination DAAs With Ultra-short Duration Therapy in Subjects With HCV Genotype 1b Infection (YANGTZE Study)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2019

At a glance

  • Drugs Asunaprevir (Primary) ; CC 31244 (Primary) ; Daclatasvir (Primary) ; Sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms YANGTZE
  • Most Recent Events

    • 22 Jan 2019 According to a Cocrystal Pharma media release, this study is expected to commence in Q1 2019.
    • 03 Jan 2019 Status changed from planning to not yet recruiting.
    • 15 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top